Biohaven nets $125M ahead of NDA submissions

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHNV) raised $125 million late Wednesday through the sale of 3.3 million shares at $37.25 in an upsized follow-on.

Following positive Phase III data reported this month for rimegepant for the acute treatment of migraine, the company plans to submit in 1H19 concurrent NDAs for orally dissolving tablet (ODT) and once-daily oral tablet formulations of the candidate (see "Biohaven's Orally Dissolving Tablet Meets in Phase III for Acute Migraine")...